Oasmia Pharmaceutical Ab (OASM) Return on Investment ROI from the fourth quarter of 2018 to fourth quarter of and for the year 2018, average high and low, overall ranking from Apr 30 2018 to - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Oasmia Pharmaceutical Ab  (OASM)


Oasmia Pharmaceutical Ab's ROI from its fourth quarter of 2018 to the fourth quarter of and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Oasmia Pharmaceutical Ab's ROI in the fourth quarter of 2018?
Oasmia Pharmaceutical Ab recorded a cumulative net loss of $-118 million during 12 months ending in the fourth quarter of 2018, resulting in a negative return on investment (ROI) of -112.37%.

Within the Healthcare sector 587 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2018 from 0 to 4290.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Apr 30 2018)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Investment Change TTM 163.32 % 177.72 % 401.74 % - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 105 105 105 105 34
Return On Investment (TTM) -112.37 % 0 % 0 % 0 % 0 %
OASM's Overall Ranking # 4290 # 0 # 0 # 0 #
Seq. Investment Change TTM 20.39 % 13.24 % 16.48 % 65.83 % 26.97 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -118 0 0 0 0

OASM Company Profile >> Back to OASM Roi Comparisons >> See Annual OASM Return On Investment



Return On Investment OASM's Ranking
Within: No.
Industry # 293
Sector # 588
Overall # 4290

Return On Investment Statistics
High Average Low
-112.37 %
-112.37 %
-112.37 %
(Apr 30 2018)  







Financial Statements
Oasmia Pharmaceutical Ab's IV. Quarter Investments $ 105 Millions OASM's Balance sheet
Oasmia Pharmaceutical Ab's IV. Quarter Income $ -118 Millions Quarterly OASM's Income Statement
OASM's Income by Division See OASM's Income by Division


OASM Annual Return On Investment (Apr 30 2018)
2018



Total Investments in Millions 105 0 0 0 0
Y / Y Investment Growth - - - - -
Net Income in Millions -14 0 0 0 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -13.54 % - - - -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
OASM's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for OASM's Competitors
Subscribers only: Roi for Oasmia Pharmaceutical Ab's Suppliers
Subscribers only: Return On Investment for OASM's Customers

Other Ratios
OASM's Roa OASM's Inventory Turnover Ratio OASM's Growth Rates OASM's Dividend Statistics
OASM's Profitability Ratios OASM's Asset Turnover Ratio OASM's Dividend Growth
OASM's Roe OASM's Valuation Ratios OASM's Financial Strength Ratios OASM's Dividend Payout Ratio



Companies with similar Return On Investment at Apr 30 2018, within Healthcare Sector ROI

Date modified: 2026-09-18T13:11:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.